International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community

Maryam Bagheri 1 , Azarakhsh Mokri 2 , Aliakbar Khosravi 1 and Kourosh Kabir 3 , *
Authors Information
1 Central Tehran Branch, Islamic Azad University, Tehran, IR Iran
2 Clinical Department, Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, IR Iran
3 Community Medicine Department, School of Medicine, Alborz University of Medical Sciences, Karaj, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: September 01, 2015, 4 (3); e23903
  • Published Online: September 1, 2015
  • Article Type: Research Article
  • Received: September 26, 2014
  • Revised: December 10, 2014
  • Accepted: January 4, 2015
  • DOI: 10.5812/ijhrba.23903

To Cite: Bagheri M, Mokri A, Khosravi A, Kabir K. Effect of Abstinence on Depression, Anxiety, and Quality of Life in Chronic Methamphetamine Users in a Therapeutic Community, Int J High Risk Behav Addict. 2015 ; 4(3):e23903. doi: 10.5812/ijhrba.23903.

Copyright © 2015, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012; 379(9810): 55-70[DOI][PubMed]
  • 2. Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006; 31(5): 301-13[PubMed]
  • 3. Singleton J, Degenhardt L, Hall W, Zabransky T. Mortality among amphetamine users: a systematic review of cohort studies. Drug Alcohol Depend. 2009; 105(1-2): 1-8[DOI][PubMed]
  • 4. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1575-86[DOI][PubMed]
  • 5. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 382(9904): 1564-74[DOI][PubMed]
  • 6. Romanelli F, Smith KM. Clinical effects and management of methamphetamine abuse. Pharmacotherapy. 2006; 26(8): 1148-56[DOI][PubMed]
  • 7. Winslow BT, Voorhees KI, Pehl KA. Methamphetamine abuse. Am Fam Physician. 2007; 76(8): 1169-74[PubMed]
  • 8. Tucker P. Substance misuse and early psychosis. Australas Psychiatry. 2009; 17(4): 291-4[DOI][PubMed]
  • 9. Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010; 105(6): 991-1002[DOI][PubMed]
  • 10. Lake CR, Quirk RS. CNS stimulants and the look-alike drugs. Psychiatr Clin North Am. 1984; 7(4): 689-701[PubMed]
  • 11. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007; 47: 681-98[DOI][PubMed]
  • 12. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol (Phila). 2010; 48(7): 675-94[DOI][PubMed]
  • 13. Suzuki O, Hattori H, Asano M, Oya M, Katsumata Y. Inhibition of monoamine oxidase by d-methamphetamine. Biochem Pharmacol. 1980; 29(14): 2071-3[PubMed]
  • 14. Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45: 54-63[DOI][PubMed]
  • 15. Rusyniak DE. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin North Am. 2013; 36(2): 261-75[DOI][PubMed]
  • 16. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R, et al. Anxiety disorders among methamphetamine dependent adults: association with post-treatment functioning. Am J Addict. 2010; 19(5): 385-90[DOI][PubMed]
  • 17. Srisurapanont M, Ali R, Marsden J, Sunga A, Wada K, Monteiro M. Psychotic symptoms in methamphetamine psychotic in-patients. Int J Neuropsychopharmacol. 2003; 6(4): 347-52[DOI][PubMed]
  • 18. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, et al. Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction. 2010; 105(10): 1809-18[DOI][PubMed]
  • 19. Iudicello JE, Woods SP, Vigil O, Scott JC, Cherner M, Heaton RK, et al. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence. J Clin Exp Neuropsychol. 2010; 32(7): 704-18[DOI][PubMed]
  • 20. Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005; 2(4): 194-9[PubMed]
  • 21. Gettig JP, Grady SE, Nowosadzka I. Methamphetamine: putting the brakes on speed. J Sch Nurs. 2006; 22(2): 66-73[PubMed]
  • 22. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry. 1974; 7: 151-69[PubMed]
  • 23. Beck AT, Rial WY, Rickels K. Short form of depression inventory: cross-validation. Psychol Rep. 1974; 34(3): 1184-6[PubMed]
  • 24. Furlanetto LM, Mendlowicz MV, Romildo Bueno J. The validity of the Beck Depression Inventory-Short Form as a screening and diagnostic instrument for moderate and severe depression in medical inpatients. J Affect Disord. 2005; 86(1): 87-91[DOI][PubMed]
  • 25. Scogin F, Beutler L, Corbishley A, Hamblin D. Reliability and validity of the short form Beck Depression Inventory with older adults. J Clin Psychol. 1988; 44(6): 853-7[PubMed]
  • 26. Cattell RB, Scheier IH. Handbook for the IPAT Anxiety Scale Questionnaire: Self Analysis Form. 1963;
  • 27. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992; 305(6846): 160-4[PubMed]
  • 28. Hojat M, Shapurian R, Mehryar AH. Psychometric properties of a Persian version of the short form of the Beck Depression Inventory for Iranian college students. Psychol Rep. 1986; 59(1): 331-8[DOI][PubMed]
  • 29. Hojat M, Shapurian R, Mehryar AH. Dimensionality of the short form of the Beck Depression Inventory: a study with Iranian college students. Psychol Rep. 1986; 59(3): 1069-70[DOI][PubMed]
  • 30. Dadsetan P, Mansour M. Mental disorders. 1989;
  • 31. Montazeri A, Goshtasebi A, Vahdaninia M, Gandek B. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005; 14(3): 875-82[PubMed]
  • 32. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005; 100(9): 1320-9[DOI][PubMed]
  • 33. McKetin R, Lubman DI, Lee NM, Ross JE, Slade TN. Major depression among methamphetamine users entering drug treatment programs. Med J Aust. 2011; 195(3)-5[PubMed]
  • 34. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, et al. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. J Nerv Ment Dis. 2009; 197(4): 225-31[DOI][PubMed]
  • 35. Mancino MJ, Gentry BW, Feldman Z, Mendelson J, Oliveto A. Characterizing methamphetamine withdrawal in recently abstinent methamphetamine users: a pilot field study. Am J Drug Alcohol Abuse. 2011; 37(2): 131-6[DOI][PubMed]
  • 36. Newton TF, Kalechstein AD, Duran S, Vansluis N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004; 13(3): 248-55[DOI][PubMed]
  • 37. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004; 61(1): 73-84[DOI][PubMed]
  • 38. Berman SM, Voytek B, Mandelkern MA, Hassid BD, Isaacson A, Monterosso J, et al. Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse. Mol Psychiatry. 2008; 13(9): 897-908[DOI][PubMed]
  • 39. Shoptaw S, Huber A, Peck J, Yang X, Liu J, Jeff D, et al. Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2006; 85(1): 12-8[DOI][PubMed]
  • 40. Zorick T, Sugar CA, Hellemann G, Shoptaw S, London ED. Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine. Drug Alcohol Depend. 2011; 118(2-3): 500-3[DOI][PubMed]
  • 41. Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord. 2012; 143(1-3): 257-60[DOI][PubMed]
  • 42. Nejtek VA, Avila M, Chen LA, Zielinski T, Djokovic M, Podawiltz A, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. J Clin Psychiatry. 2008; 69(8): 1257-66[PubMed]
  • 43. Hanley MJ, Kenna GA. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm. 2008; 65(7): 611-8[DOI][PubMed]
  • 44. Ersche KD, Roiser JP, Abbott S, Craig KJ, Muller U, Suckling J, et al. Response perseveration in stimulant dependence is associated with striatal dysfunction and can be ameliorated by a D(2/3) receptor agonist. Biol Psychiatry. 2011; 70(8): 754-62[DOI][PubMed]
  • 45. Gonzales R, Ang A, Glik DC, Rawson RA, Lee S, Iguchi MY, et al. Quality of life among treatment seeking methamphetamine-dependent individuals. Am J Addict. 2011; 20(4): 366-72[DOI][PubMed]
  • 46. Gonzales R, Ang A, Marinelli-Casey P, Glik DC, Iguchi MY, Rawson RA, et al. Health-related quality of life trajectories of methamphetamine-dependent individuals as a function of treatment completion and continued care over a 1-year period. J Subst Abuse Treat. 2009; 37(4): 353-61[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments